Should the British health service pay for the expensive-yet-effective hepatitis C treatment Sovaldi? The U.K.'s cost-effectiveness gatekeepers say they're not convinced.
written on 16.06.2014
U.K. gatekeepers nix hep C drug Sovaldi till Gilead ponies up more evidence
